Slide 1: Focus on key business development projects – generics and innovation
Focus on key business development projects – generics and innovation Summary of 1Q 2022 M a y 2 0 2 2 1
Slide 2: Financial Highlights
Financial Highlights 2
Slide 3: EBITDA of the branded generics segment remains robust
EBITDA of the branded generics segment remains robust. Focus on R&D projects resulted in a slow down of sales in 1Q22 which was translated into EBITDA decrease of the Company. BRANDED GENERICS INNOVATIVE PRODUCTS (R&D) TOTAL Revenues Revenues Revenues 47,4 41,9 44,3 33,3 8,7 3,1 1Q22 1Q21 1Q22 1Q21
Slide 4: Group and Segment P&L Details
Group and Segment P&L Details Branded generics segment Innovation segment Total PLN million 1Q22 1Q21 1Q22 1Q21 1Q22 1Q21 Revenues from sales of medicines 32,9 43,2 0,0 0,0 32,9 43,2 Other revenues 0,3 0,9 0,0 0,0 0,3 0,9 Revenues from grants 0,0 0,0 8,7 3,1 8,7 3,1 Revenues from sales of licences 0
Slide 5: Balance sheet
Balance sheet PLN mln 2022-03-31 2021-12-31 A. In 1Q22 the Company maintains stable levels of CAPEX ASSETS 676,3 707,1 hence tangible assets record similar levels of nearly PLN Non-current assets 412,8 428,4 Property, plant and equipment A 302,6 303,7 330m both as at 31Mar22 and 31Dec21. Right-of-us
Slide 6: Sales
rm) = © ep)
Slide 7: Q1 2022 - Export sales slow down due to absorption of production capacities by new products
Q1 2022 - Export sales slow down due to significant absorbtion of production capacities by new products Sales dynamics for the last 5 quarters 30,0 28,4 25,0 25,7 22,8 20,0 21,0 20,4 15,0 *a consequence of allocating 10,0 significant production capacity to the trial series for the 5,0 implementation
Slide 8: Robust market position of key products promoted in Poland
Robust market position of key products promoted in Poland (value stake in ATC3 class*) 10,0 20,0 20,0 20,0 9,0 18,0 18,0 18,0 8,0 16,0 16,0 16,0 14,0 14,0 14,0 7,0 12,0 12,0 12,0 6,0 10,0 10,0 10,0 5,0 8,0 8,0 8,0 4,0 6,0 6,0 6,0 3,0 4,0 4,0 4,0 2,0 2,0 2,0 2,0 1,0 0,0 0,0 0,0 2021 I-IV 2022 I-IV 20
Slide 9: Key R&D projects status
Key R&D projects status Clinical Development Molecule Indication Research Preclinical Phase 1 Phase 2 FDA Approved Falkieri TRD depression Investigational New Drug (IND) Schizophrenia/ CPL’36 post-infiltration dyskinesia (LiD) Diabetes/ CPL’280 diabetic neuropathies Solid tumors CPL’110 (bladder, lu
Slide 10: Thank you for your attention
Thank you for your attention Q&A session. 10